Format

Send to

Choose Destination
Transplant Proc. 2004 Mar;36(2 Suppl):291S-294S.

Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation.

Author information

1
Liver Transplant Unit, Hospital Universitario de Belvitge, L'Hospitalet de Llobregat, Barcelona, Spain. t.casanovas@csub.scs.es

Abstract

Over the last 20 years, immunosuppression protocols in liver transplant patients have been based on calcineurin inhibitors, such as cyclosporine (CsA). Currently, there are three outstanding clinical issues related to the use of CsA in the liver transplant setting that merit further attention: (1) dose adjustment according to 2-hour postdose (instead of trough) concentrations to improve efficacy and safety, (2) possible synergistic effect between CsA and antiviral treatments for recurrent posttransplant hepatitis C infection, and (3) preliminary results showing favorable outcomes after liver transplantation in HIV-positive patients receiving antiviral therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center